Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

353 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Cross-reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barré or Miller Fisher syndrome.
Jacobs BC, Hazenberg MP, van Doorn PA, Endtz HP, van der Meché FG. Jacobs BC, et al. Among authors: van doorn pa, van der meche fg. J Infect Dis. 1997 Mar;175(3):729-33. doi: 10.1093/infdis/175.3.729. J Infect Dis. 1997. PMID: 9041356
Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial.
van Koningsveld R, Schmitz PI, Meché FG, Visser LH, Meulstee J, van Doorn PA; Dutch GBS study group. van Koningsveld R, et al. Among authors: van doorn pa. Lancet. 2004 Jan 17;363(9404):192-6. doi: 10.1016/s0140-6736(03)15324-x. Lancet. 2004. PMID: 14738791 Clinical Trial.
Small volume plasma exchange for Guillain-Barré syndrome in resource-limited settings: a phase II safety and feasibility study.
Islam B, Islam Z, Rahman S, Endtz HP, Vos MC, van der Jagt M, van Doorn PA, Jacobs BC, Mohammad QD. Islam B, et al. Among authors: van der jagt m, van doorn pa. BMJ Open. 2018 Aug 17;8(8):e022862. doi: 10.1136/bmjopen-2018-022862. BMJ Open. 2018. PMID: 30121613 Free PMC article. Clinical Trial.
HLA class II alleles are not a general susceptibility factor in Guillain-Barré syndrome.
Geleijns K, Schreuder GM, Jacobs BC, Sintnicolaas K, van Koningsveld R, Meulstee J, Laman JD, van Doorn PA. Geleijns K, et al. Among authors: van koningsveld r, van doorn pa. Neurology. 2005 Jan 11;64(1):44-9. doi: 10.1212/01.WNL.0000148727.02732.01. Neurology. 2005. PMID: 15642902
The occurrence of Guillain-Barre syndrome within families.
Geleijns K, Brouwer BA, Jacobs BC, Houwing-Duistermaat JJ, van Duijn CM, van Doorn PA. Geleijns K, et al. Among authors: van duijn cm, van doorn pa. Neurology. 2004 Nov 9;63(9):1747-50. doi: 10.1212/01.wnl.0000143055.09646.31. Neurology. 2004. PMID: 15534275
Quality of life complements traditional outcome measures in immune-mediated polyneuropathies.
Merkies IS, Schmitz PI, van der Meché FG, Samijn JP, van Doorn PA; Inflammatory Neuropathy Cause and Treatment (INCAT) group. Merkies IS, et al. Among authors: van der meche fg, van doorn pa. Neurology. 2002 Jul 9;59(1):84-91. doi: 10.1212/wnl.59.1.84. Neurology. 2002. PMID: 12105312
Antiganglioside antibodies in polyneuropathy associated with monoclonal gammopathy.
Eurelings M, Ang CW, Notermans NC, Van Doorn PA, Jacobs BC, Van den Berg LH. Eurelings M, et al. Among authors: van doorn pa, van den berg lh. Neurology. 2001 Nov 27;57(10):1909-12. doi: 10.1212/wnl.57.10.1909. Neurology. 2001. PMID: 11723289
Anti-neuroblastoma cell line antibodies in inflammatory demyelinating polyneuropathy: inhibition in vitro and in vivo by IV immunoglobulin.
van Doorn PA, Brand A, Vermeulen M. van Doorn PA, et al. Neurology. 1988 Oct;38(10):1592-5. doi: 10.1212/wnl.38.10.1592. Neurology. 1988. PMID: 2843794
Assessing grip strength in healthy individuals and patients with immune-mediated polyneuropathies.
Merkies IS, Schmitz PI, Samijn JP, Meché FG, Toyka KV, van Doorn PA. Merkies IS, et al. Among authors: van doorn pa. Muscle Nerve. 2000 Sep;23(9):1393-401. doi: 10.1002/1097-4598(200009)23:9<1393::aid-mus10>3.0.co;2-o. Muscle Nerve. 2000. PMID: 10951442
Chronic inflammatory demyelinating polyneuropathy (CIDP).
Van der Meché FG, Van Doorn PA. Van der Meché FG, et al. Among authors: van doorn pa. Electroencephalogr Clin Neurophysiol Suppl. 1999;50:493-8. Electroencephalogr Clin Neurophysiol Suppl. 1999. PMID: 10689499 Review. No abstract available.
353 results
Jump to page
Feedback